It sounds like you're saying saying that "orphan drugs" can benefit 10% of the population and are also "cash cows." Do I have that right? I ask because if that's true, it seems to me that this is a good thing. If it wasn't a cash cow, would companies still be incentivized to take on the risk of researching these drugs and going through the work of having them tested and approved?

Your post seems critical of Google, but I don't know if that makes sense. Isn't your main criticism with the healthcare system and laws surrounding it? I don't know if we can blame companies that operate within existing law. The blame should instead be passed to policy makers and their voters.